| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PARC |
| Uniprot No | P55774 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-89aa |
| 氨基酸序列 | Alternative macrophage activation associated CC chemokine 1; Alternative macrophage activation-associated CC chemokine 1; AMAC-1; AMAC1; CC chemokine PARC; CCL18; CCL18(4-69); CCL18_HUMAN; CKb7; DC-CK1; DCCK1 ; DCCK1; Dendritic cell chemokine 1; Macrophage inflammatory protein 4; MIP-4; MIP4; PARC; Pulmonary and activation regulated chemokine; Pulmonary and activation-regulated chemokine; SCYA18; Small inducible cytokine A18 ; Small inducible cytokine A18; Small-inducible cytokine A18 |
| 预测分子量 | 7.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PARC(P53 Apoptosis Effector Related to PMP22)重组蛋白研究的虚构参考文献示例(仅供格式参考，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *Structural Characterization of PARC Recombinant Protein in Apoptosis Regulation*
**作者**: Smith J.D., et al.
**摘要**: 通过X射线晶体学解析了PARC重组蛋白的三维结构，揭示了其与p53结合的潜在结构域，并验证了其在抑制细胞凋亡中的功能。
2. **文献名称**: *Functional Analysis of PARC in Mitochondrial Apoptotic Pathways*
**作者**: Chen L., Wang H.
**摘要**: 利用重组PARC蛋白进行体外实验，证明其通过隔离细胞质中的p53.抑制线粒体途径的凋亡信号，为癌症耐药性研究提供新视角。
3. **文献名称**: *PARC Recombinant Protein as a Biomarker in Neurodegenerative Diseases*
**作者**: Gupta R., et al.
**摘要**: 在小鼠模型中表达重组PARC蛋白，发现其通过调节Bcl-2家族蛋白的表达延缓神经退行性病变进程。
4. **文献名称**: *Development of PARC-Targeted Therapeutic Strategies Using Recombinant Protein Screening*
**作者**: Müller S., et al.
**摘要**: 基于重组PARC蛋白的高通量药物筛选平台，发现小分子抑制剂可解除PARC对p53的抑制，增强化疗敏感性。
---
**提示**：实际研究中，建议通过PubMed、Web of Science等平台搜索关键词“PARC protein recombinant”或“PARC apoptosis”获取真实文献。部分经典研究可能涉及PARC与p53、癌症或神经疾病的关联机制。
**Background of PARC Recombinant Protein**
PARC (p53-associated Parkin-like cytoplasmic protein), also known as Cullin-9 (CUL9), is a multifunctional protein encoded by the *CUL9* gene. Initially identified in 2003. PARC belongs to the Cullin family, which serves as scaffold proteins in E3 ubiquitin ligase complexes critical for ubiquitin-mediated proteolysis. Unlike other Cullins, PARC lacks a canonical N-terminal adaptor-binding domain but contains a conserved C-terminal Cullin homology region and a Parkin-like ubiquitin ligase domain.
PARC gained attention due to its interaction with p53. a tumor suppressor protein. It sequesters p53 in the cytoplasm, inhibiting its nuclear translocation and pro-apoptotic functions, thereby promoting cell survival under stress conditions. This regulatory mechanism links PARC to cancer biology, particularly in tumors where cytoplasmic retention of p53 correlates with chemoresistance. Additionally, PARC shares structural similarities with Parkin, a protein implicated in Parkinson’s disease, suggesting potential roles in neuronal homeostasis and neurodegenerative disorders.
Recombinant PARC proteins are engineered using expression systems (e.g., *E. coli*, mammalian cells) to study its biochemical properties, ubiquitination activity, and interactions with partners like p53 or components of the ubiquitin-proteasome system. These tools aid in elucidating PARC’s dual roles in cancer progression and neuroprotection, as well as its therapeutic potential. Research on PARC recombinant proteins continues to explore its context-dependent functions, offering insights into targeted therapies for diseases involving dysregulated protein degradation or apoptosis pathways.
×
